• In past months, multiple law firms including Pomerantz, Bernstein Liebhard, and others filed securities class action lawsuits against Lufax Holding, alleging false or misleading disclosures, weak internal controls, and issues tied to its decision to remove auditor PricewaterhouseCoopers over concerns about 2022–2023 financial reporting.
• An important angle for investors is that these parallel lawsuits all center on alleged misstatements across the same 2023–2025 period, concentrating both legal and reputational risk into a single contested chapter of Lufax’s corporate history.
• With allegations around inadequate internal controls now in focus, we’ll examine how this wave of litigation shapes Lufax Holding’s broader investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Lufax Holding's Investment Narrative?

To own Lufax today, you really have to believe the company can turn persistent losses into a sustainable, well-governed consumer finance platform, while trading at what looks like a low sales multiple. Previously, the near-term story revolved around stabilising revenue at about CNY 27,127.61 million, narrowing losses from CNY 3,870.62 million to CNY 2,097.68 million, and bedding in a new CEO and an almost entirely refreshed board. The latest wave of securities class actions, all targeting the same 2023 to early 2025 period and tied to PwC’s removal, now cuts straight into those catalysts by questioning the reliability of the very numbers underpinning the turnaround case. Short term, that shifts the spotlight from growth back to legal exposure, internal controls and governance credibility.

However, investors should not overlook how concentrated these internal control allegations really are. Insights from our recent valuation report point to the potential undervaluation of Lufax Holding shares in the market.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates, between US$2.28 and US$2.77, underline how differently people price Lufax, especially with lawsuits and governance questions now framing the business outlook.

Explore 2 other fair value estimates on Lufax Holding - why the stock might be worth as much as 48% more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lufax Holding research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lufax Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lufax Holding's overall financial health at a glance.

No Opportunity In Lufax Holding?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.